155388-63-9

Basic information

• Product Name: TERT-BUTYL 2-HYDROXY-5-NITROBENZOATE
• Synonyms: TERT-BUTYL 2-HYDROXY-5-NITROBENZOATE;2-Hydroxy-5-nitro-benzoic acid tert-butyl ester
• CAS NO: 155388-63-9
• Molecular Formula: C₁₁H₁₃NO₅
• Molecular Weight: 239.22462
• Mol File: 155388-63-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 82 °C
• Boiling Point: 350.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.278±0.06 g/cm3(Predicted)
• PKA: 5.44±0.16(Predicted)
• CAS DataBase Reference: TERT-BUTYL 2-HYDROXY-5-NITROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 2-HYDROXY-5-NITROBENZOATE(155388-63-9)
• EPA Substance Registry System: TERT-BUTYL 2-HYDROXY-5-NITROBENZOATE(155388-63-9)

Safety Data

• Hazardous Substances Data: 155388-63-9(Hazardous Substances Data)

Upstream product

• 96-97-9 5-nitrosalicylic acid 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 508210-93-3 tert-Butyl 2-benzhydryloxy-5-nitrobenzoate 
• 1427469-71-3 C₁₅H₂₁NO₅ 
• 1427469-77-9 C₁₅H₁₅NO₅ 
• 1427469-75-7 2-(2-(tert-butoxycarbonyl)-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)acetic acid 
• 1427469-73-5 tert-butyl 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-(2-ethoxy-2-oxoethoxy)benzoate 
• 1427469-69-9 tert-butyl 2-(2-ethoxy-2-oxoethoxy)-5-nitrobenzoate 
• 1422054-54-3 C₂₁H₂₄N₂O₅ 
• 508211-74-3 tert-Butyl 2-[bis(4-fluorophenyl)methoxy]-5-nitrobenzoate 
• 155388-93-5 5-aminosalicylic acid tert-butyl ester 

Relevant articles and documents

BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS

Bifunctional compounds that increase uric acid excretion and reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders of uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are provided. Pharmaceutical compositions comprising the bifunctional compounds are also provided.

Azo-reductase activated budesodine prodrugs for colon targeting

Budesodine is a synthetic glurocorticoid that undergoes substantial first pass metabolism, limiting systemic exposure. Its use in treatment of inflammatory bowel disease would benefit from a targeting strategy that could lead to a local topical effect, improving safety and increasing anti-inflammatory efficacy. A two-step prodrug strategy involving azoreduction/cyclization that we developed previously for prednisolone is here applied with some variations to budesonide. The budesodine prodrugs were tested using an in vitro azoreductase assay simulating human colonic microflora. The kinetics of amino steroid ester cyclization and its pH dependence was also evaluated. The stability of the prodrugs systems in simulated human duodenal and gastric fluid was evaluated to determine the likelihood of intact intestinal transit. The propionic acid derived prodrug 3 undergoes rapid activation by Clostridium perfingens and its putative reduction product cyclizes with acceptable rapidity when synthesized independently. These properties of 3 suggest that it has potential in management of ulcerative colitis.

TARGETING DIAZO PRODRUGS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Provided herein are compounds, compositions and methods for decreasing NFkB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD).